Non-Invasive Microcirculatory Device Could Help COVID-19 Patients

According to the Centers for Disease Control and Prevention, nearly 90 percent of Americans being hospitalized with COVID-19 have an underlying medical condition. Healthcare technology company Circularity Healthcare, creator of D’OXYVA, is looking to help these patients treat those conditions faster to better their chances of recovery. D’OXYVA (deoxyhemoglobin vasodilator), the first biotech solution of its kind, provides non-invasive, transdermal microcirculation to improve overall oxygen-rich blood flow—an effective treatment option for a variety of conditions including diabetes, hypertension, cardiovascular issues, COPD, and high blood pressure.
 
“D’OXYVA is aimed at helping millions of people improve their health and their immune response,” said Circularity Healthcare CEO Norbert Kiss. “We are confident this device can save lives in the fight against the coronavirus by helping repair the body’s functions in people with underlying conditions.” D’OXYVA speeds up the body’s healing process by improving micro and macro circulation and the autonomic nervous system (ANS), detoxifying the liver and kidney, reducing inflammation, and increasing oxygenation and delivery of nutrients.  It is the only clinically-tested, non-invasive, portable, transdermal microcirculatory regenerative solution device. 
 
The over-the-counter product is intended to ease the expense and inconvenience of time-consuming doctor visits by offering affordable and effective management of conditions that can take place in the comfort of your own home. “This is truly the future of optimized healthcare,” said Kiss. “D’OXVYA provides an advanced technology that offers a painless solution to help people manage chronic health conditions and see measurable results within a matter of weeks. This is a great way to save time and money by reducing the reliance on opioids and other expensive medications and office visits.” 
 
Extensive clinical research conducted over an eight-year period has already shown incredible success rates. Trials have included over three dozen human clinical studies including double-blind, randomized, and placebo-controlled studies at Pennsylvania State University. The company is now significantly expanding Phase 3 human clinical trials working with the top 10 universities in the United States targeting underlying conditions specific to COVID-19 risk factors such as oxygen-rich microcirculation in lungs, the heart, kidneys and other vital organs as well as inflammatory markers.
 
The science used to create the device received a 2019 Nobel Prize in Physiology Medicine. D’OXYVA works by utilizing U.S. Food and Drug Administration (FDA)-cleared, non-toxic molecules (over-the-skin deoxyhemoglobin vasodilator) that deliver a vapor of pharmaceutical-grade CO₂ and water to the peripheral microcirculation. This vapor is delivered through the placement of the D’OXYVA device over the thumb for a five-minute period. The CO₂ then travels into the microcirculation of the skin, where it causes a vasodilation that leads to increased perfusion. Since its introduction in 2012, the physician-recommended, easy-to-use device has helped users track and regain their health by repairing or growing new vessels and significantly improving nerve activities in the body.  
 
“The fact is that D’OXYVA increases the effectiveness of the microcirculatory system,” said Dr. Jim Bledsoe, Ph.D., and holistic practitioner. “Increasing the blood flow will help the body improve itself.”
 
D’OXYVA is currently available over the counter online.
 
The company is actively accepting donation requests from nurses and doctors to provide D’OXYVA for immediate lifesaving treatment of hospital patients in critical condition due to its Investigational Device Exemption (IDE) status under FDA regulations.